Precigen Stock Has To Grow Into Its Valuation (NASDAQ:PGEN)
· seekingalpha.com
Precigen (PGEN) jumped on PAPZIMEOS FDA approval, but a premium valuation and single-drug reliance hurt risk/reward. See more details here.
Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamenta...